Axogen CFO Says $34 Million Nerve Tape Forecast Is Net Of Cannibalization
Lindsey Hartley said the 2027 nerve tape figure is incremental, while 2026 guidance models an overlap she would not size.
Axogen's nerve tape forecast of $34 million for next year is incremental and already net of cannibalization, CFO Lindsey Hartley said on the company's third-quarter earnings call Wednesday. The company, which sells products surgeons use to repair damaged peripheral nerves, raised its 2026 revenue outlook to at least $290 million after buying BioCircuit.
Net of cannibalization, but unsized
A Wells Fargo analyst asked how much of the nerve tape business would be new versus taken from Axogen's own products. Hartley said the $34 million she put out in the press release at the deal's closing is incremental, net of cannibalization, with more guidance due in the first quarter.
On 2026, she said the expected overlap between BioCircuit's nerve tape and Axogen's Axoguard connector and protector products sits inside organic growth guidance of at least 26%. "We're not going to guide to the exact amount of cannibalization that we are anticipating," she said, adding that the company modeled an assumption and will keep testing it as integration proceeds.
Asked by a Jefferies analyst how surgeons are moving from connector to tape, CEO Michael Dale said the rollout is just underway and he could speak only to "great enthusiasm." He argued tape is far broader than the connector, which will still be used for specific procedures while tape targets large gaps and direct repair. Dale put direct repair at roughly 40% to 50% of transected nerve procedures, an underdeveloped opportunity.
Raised outlook after BioCircuit
Axogen completed the BioCircuit purchase on October 1, funding the $200 million price plus expenses. Third-quarter revenue was $75.8 million, up 26.2% from a year earlier, with net income of $2.3 million and adjusted EBITDA of $13.4 million.
Full-year guidance now calls for revenue growth of at least 29%, including at least $7 million from BioCircuit, and organic revenue of at least $283 million. Gross margin is still expected at 73% or better, though a step-up in the value of acquired inventory could weigh on it in the fourth quarter and the full year.
Jens, an Axogen executive, said BioCircuit had about 400 active accounts against Axogen's footprint of close to 3,000. He put combined connector and nerve tape penetration of the procedure market at around 5%.
Prostate plans and the next guidance
Dale said Axogen will start prostate nerve reconstruction market development in 2027, with clinical detail due November 9 and financials at a March 2027 investor day. Prostate is not in current or long-range guidance.
Hartley said formal 2027 guidance comes in the first quarter, and that she expects 2027 gross margin to look much like 2026's. Dale said BioCircuit results will be published on a pro forma basis from quarter to quarter.
Formal 2027 guidance in the first quarter will show how much overlap Axogen builds into next year's nerve tape number.
Sources
- Axogen maintains 2026 revenue outlook of at least $290M after strong Q3 (AXGN:NASDAQ) — seekingalpha.com
- Axogen, Inc. Reports Third Quarter 2026 Financial Results — globenewswire.com